{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056889","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.638388+00:00","generated_at":"2026-06-15T11:49:55.349361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma reports record Q1 revs $106.8M (+65.6% YoY), raises FY2023 guidance across all metrics","bullets":["Record net revenue of $106.8M, up 65.6% YoY; GAAP net income $1.0M, diluted EPS $0.06.","Adjusted non-GAAP EBITDA $33.0M (vs $4.3M Q1 2022); adj. diluted EPS $1.17 (vs -$0.12).","Cortrophin Gel net sales $16.3M (Q1 2022: $1.3M); FY guidance maintained at $80-90M.","Raised FY2023 guidance: rev $385-410M (from $360-385M), adj. EBITDA $97-107M, adj. EPS $2.99-3.45.","Generics revenue $63.7M (+29.7% YoY); established brands/other $26.7M (+90.0%). FDA inspection with zero 483s."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056889","json":"https://secwatch.observer/filing/0001104659-23-056889.json","markdown":"https://secwatch.observer/filing/0001104659-23-056889.md","text":"https://secwatch.observer/filing/0001104659-23-056889.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/tm2314831d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:49:55.349361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84e0b431077242399a38d93a10cb1d4d1f928667","claim":"ANI PHARMACEUTICALS INC reported full-year 2023 results: revenue $385 million to $410 million, EPS $2.99 to $3.45. Guidance raised.","evidence_excerpt":"Full Year 2023 Guidance -- Raises Company net revenue guidance to $385 million to $410 million from $360 million to $385 million; adjusted non-GAAP EBITDA guidance to $97 million to $107 million from $78 million to $88 million; adjusted non-GAAP earnings per share to $2.99 to $3.45 from $2.09 to $2.59","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2023"},{"label":"Revenue","value":"$385 million to $410 million"},{"label":"EPS","value":"$2.99 to $3.45"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"9ac62b5c87c1e2a90062ce29addff1915459336d","claim":"ANI PHARMACEUTICALS INC reported quarter ended March 31, 2023 results: revenue $106.8 million, net income $1.0 million, EPS $0.06.","evidence_excerpt":"First Quarter 2023 Financial Results -- Record quarterly net revenues of $106.8 million, representing year-over-year growth of 65.6%; 2023 first-quarter net income available to common shareholders of $1.0 million and diluted GAAP income per share of $0.06","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1023024/000110465923056889/0001104659-23-056889-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2023"},{"label":"Revenue","value":"$106.8 million"},{"label":"Net income","value":"$1.0 million"},{"label":"EPS","value":"$0.06"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}